How are emerging therapies, patient segmentation and evolving prevention strategies changing the competitive landscape in respiratory medicine?
Coverage Period: 4 Sep – 7 Oct 2026
Introduction
The defining story of this reporting period is the push to change where respiratory therapies intervene in the patient journey—from chronic maintenance toward acute treatment, prevention, earlier disease use and modification of underlying biology.
That shift was visible across asthma, chronic infection, rare genetic disease, fibrosis and respiratory viruses. Developers advanced biologics for acute exacerbations, localized airway therapies designed to act at the site of disease, longer-duration antibodies, RNA editing and first-in-class antifibrotic mechanisms. At the same time, regulatory developments showed how established therapies may gain value by moving earlier in treatment or into prevention. Competition is therefore broadening beyond efficacy within existing care models toward therapies that could redefine timing, route, duration and purpose of treatment.
Companies Covered: Connect Biopharma, Vial, Leyden Labs, RIGImmune, Rezubio, Wave Life Sciences, Mediar Therapeutics, Eli Lilly, Insmed, Shionogi.
Disease Areas Covered: Asthma, Alpha-1 Antitrypsin Deficiency (AATD), Idiopathic Pulmonary Fibrosis (IPF), Mycobacterium avium Complex (MAC) Lung Disease, COVID-19.
Executive Summary
- Asthma development is expanding beyond chronic maintenance. Acute exacerbation treatment, virus-trigger prevention, dual-pathway blockade and extended dosing are creating new ways to differentiate biologics beyond established severe-asthma maintenance models. Rademikibart, RIG-101 and Vial’s IL-13 x TSLP program illustrate this widening competitive field
- Localized respiratory delivery is becoming an important platform strategy. Inhaled and intranasal approaches are being designed to increase exposure at the lung or respiratory mucosa while limiting systemic exposure or acting closer to the point of infection and inflammation. Rezubio and Leyden Labs provide early examples, although clinical differentiation remains to be demonstrated.
- Disease modification is moving closer to clinical validation in rare and progressive lung disease. RNA editing in alpha-1 antitrypsin deficiency and new fibrosis targets in idiopathic pulmonary fibrosis are testing whether treatment can address core disease biology rather than primarily control downstream consequences.
- Regulatory expansion is opening earlier treatment and prevention opportunities. Priority Review for an expanded ARIKAYCE indication and European authorization of ensitrelvir for post-exposure prophylaxis show how therapies can create additional value by moving earlier in disease management or preventing symptomatic disease after exposure.## Our Perspective
Watch the video summary
Strategic Perspective: How Respiratory Treatment Strategies Are Evolving
Acute Asthma Treatment and Long-Duration Biologics Expand the Competitive Model
Asthma competition is moving beyond the established model of maintenance biologics for patients with persistent severe disease. Recent programs are testing intervention during acute exacerbations, prevention of virus-triggered events and greater pathway coverage with less frequent dosing.
Connect Biopharma’s Phase 2 Seabreeze STAT study evaluated rademikibart as an add-on treatment during acute exacerbations in patients with type 2 inflammation. The study reported a statistically significant improvement in post-bronchodilator FEV1 at Day 7. Treatment failure was reduced by 66% versus placebo, but that endpoint did not reach statistical significance. Connect plans to use the findings to inform Phase 3 design and discussions with the FDA.
The commercial significance lies in the treatment setting. A biologic that can improve outcomes immediately after an acute event would occupy a different clinical role from long-term maintenance therapy and could potentially extend biologic use into hospitals, emergency settings or structured post-exacerbation care.
Other programs are testing different forms of differentiation. Vial’s IL-13 x TSLP bispecific has moved into a Phase 1b asthma study with engineering intended to support twice-yearly dosing, combining pathway breadth with potential convenience. Leyden Labs is targeting virus-induced exacerbations through intranasal activation of RIG-I, with Phase 1 biomarker results supporting progression toward a rhinovirus challenge study.
The market implication is a more segmented asthma landscape in which treatment timing, target breadth, trigger prevention and dosing interval may matter alongside efficacy. The main uncertainty is clinical validation. Rademikibart still requires a successful Phase 3 strategy, Vial must establish patient-level pharmacodynamic and clinical effects, and Leyden Labs must show that antiviral biomarker activation translates into fewer or less severe exacerbations.
Inhaled and Intranasal Delivery Strengthen Respiratory Platform Strategies
Direct delivery to respiratory tissues is becoming a more visible source of differentiation.
Rezubio began Phase 1 dosing of RZ-520 after receiving IND clearances from both the FDA and China’s NMPA. The inhaled candidate is designed to maintain drug exposure in the lung while limiting systemic distribution and is the second clinical-stage asset from the company’s membrane-anchored drug design platform.
Leyden Labs is pursuing a related localization strategy at the upper respiratory mucosa. Its acquisition of RIGImmune added both RIG-101 and the NEED intranasal delivery platform to an existing portfolio of broadly protective intranasal antibodies. Rather than relying only on systemic immune protection, the portfolio is designed to intervene where airborne viruses first encounter the host.
These programs matter because delivery itself can become part of product differentiation. Localized exposure may support improved therapeutic index, sustained tissue activity or intervention closer to the site where infection and inflammation begin. A reusable delivery technology can also provide leverage across multiple assets and indications rather than serving a single product.
For the respiratory market, this creates another axis of competition alongside target and mechanism. Companies with validated inhaled or intranasal platforms may be able to build broader franchises around airway-directed treatment.
The key uncertainty is whether localization delivers measurable clinical advantages over systemic treatment. Early pharmacokinetic, pharmacodynamic and biomarker findings are supportive, but larger patient trials will need to demonstrate that local delivery improves outcomes, tolerability, dosing or adherence enough to influence treatment decisions.
RNA Editing and New Fibrosis Targets Raise the Bar for Disease Modification
Rare and progressive respiratory diseases are seeing more direct attempts to alter core disease biology.
Wave Life Sciences received FDA feedback supporting a two-year registrational trial for WVE-006 in alpha-1 antitrypsin deficiency, with a one-year interim analysis that could support accelerated approval based on biomarkers. The RNA-editing therapy is designed to correct the Pi*ZZ-associated RNA mutation, increase functional M-AAT and reduce mutant Z-AAT. The intended result is a single approach capable of addressing both pulmonary deficiency and hepatic accumulation.
That development is important not only for AATD but also for RNA medicines more broadly. Regulatory support for a registrational strategy incorporating biomarker-based accelerated approval could provide an important test of how RNA editing can move from proof of mechanism toward late-stage development in genetically defined disease.
A different disease-modification strategy is advancing in idiopathic pulmonary fibrosis. Mediar Therapeutics completed enrollment in the 168-patient Phase 2 WISPer study of MTX-463, a first-in-class antibody targeting WISP1. The program is designed to interfere with myofibroblast-related fibrotic signaling and is being developed under a global licensing agreement that gives Eli Lilly the right to lead further development and commercialization after Phase 2.
The market implication is that future competition in AATD and IPF may depend increasingly on demonstrating effects on disease mechanisms rather than adding incremental symptomatic benefit. This could also increase the strategic value of biomarkers that connect target engagement to disease progression.
Significant uncertainty remains. Wave must show that RNA correction produces durable clinical benefit beyond biomarker changes, while Mediar must demonstrate that WISP1 inhibition translates into meaningful preservation of lung function. Upcoming multidose WVE-006 data and WISPer’s FVC results will be important tests of both approaches.
MAC Lung Disease and COVID-19 Prevention Move Treatment Earlier
Two regulatory developments during the period highlighted the commercial potential of shifting effective treatment earlier in the care pathway.
The FDA granted Priority Review to Insmed’s supplemental application for ARIKAYCE in MAC lung disease, with a PDUFA target date of January 28, 2027. ARIKAYCE currently has an accelerated approval for refractory disease in adults with limited or no alternatives. The proposed expansion is supported by the Phase 3b ENCORE study and could extend treatment to patients earlier in their disease course, including newly diagnosed patients.
If approved, that change could materially expand the addressable population and reposition ARIKAYCE from a later-line therapy toward a broader role in MAC treatment. Insmed’s planned discussions with Japanese regulators also show the potential for geographic expansion of the same strategy.
Shionogi’s European authorization of ensitrelvir for post-exposure prophylaxis of COVID-19 represents a different form of earlier intervention. Instead of treating established infection, the therapy can now be used following known exposure with the aim of preventing symptomatic disease. The authorization was supported by Phase 3 data showing a 67% reduction in symptomatic COVID-19 through Day 10 versus placebo.
Both developments show that commercial expansion can come from changing treatment timing as well as introducing new mechanisms. Moving into earlier disease or prevention can increase eligible populations and create new points of intervention.
The uncertainty is adoption. Earlier treatment requires clinicians to identify and treat patients sooner, while prophylaxis depends on timely recognition of exposure. Guidelines, workflow, safety considerations and real-world prescribing behavior will determine how much of the expanded regulatory opportunity translates into routine use.
What We Are Watching Next: Key Clinical and Regulatory Catalysts in Respiratory Drug Development
- Connect Biopharma’s FDA discussions on rademikibart Phase 3 design will indicate whether acute exacerbation treatment can become a viable new development pathway for asthma biologics.
- Wave Life Sciences’ multidose WVE-006 data will provide a key test of whether RNA editing can sustain correction of AAT biology strongly enough to support its planned registrational strategy.
- Mediar’s Phase 2 WISPer results in IPF will show whether WISP1 inhibition can translate target engagement into meaningful preservation of FVC.
- Vial’s Phase 1b asthma data and Leyden Labs’ rhinovirus challenge program should clarify whether ultra-long-duration blockade and mucosal antiviral modulation can deliver clinically relevant differentiation.
- The January 28, 2027 ARIKAYCE PDUFA decision will be an important indicator of how far an established inhaled therapy can move from refractory MAC disease into earlier treatment.
Key Takeaway: Competition in Respiratory Therapeutics Is Moving Beyond Traditional Treatment Models
The respiratory market is beginning to compete over the treatment model itself. During this reporting period, the most important programs and regulatory developments moved intervention toward acute disease, prevention, earlier treatment, localized delivery and correction of underlying pathology.
That does not mean established maintenance therapies will be displaced. It does mean future differentiation may depend on more than efficacy within an existing class. Therapies that can intervene at a more valuable point in the disease course, reduce treatment burden or address disease biology more directly could reshape how respiratory markets are segmented. The next clinical and regulatory milestones will determine which of these approaches can move from strategic promise to durable competitive advantage
🌐 Explore LucidQuest Strategic Roundups across multiple therapy areas for deeper healthcare and pharma analysis
About LucidQuest
About LucidQuest
LucidQuest helps organizations anticipate change by identifying emerging signals, market shifts, and strategic opportunities.
Learn more: www.lqventures.com
Contact us at: info@lqventures.com